Pelabresib plus ruxolitinib combination therapy in jak inhibitor-naïve patients with myelofibrosis in the phase 3 MANIFEST-2 study: Preliminary evidence of bone marrow recovery Meeting Abstract
| Authors: | Mascarenhas, J.; Rampal, R. K.; Vannucchi, A. M.; Gupta, V.; Oh, S. T.; Kuykendall, A. T.; Mesa, R.; Kiladjian, J. J.; Talpaz, M.; Kremyanskaya, M.; Scandura, J.; Kräft, T.; Eliane, J. P.; Chang, T. W.; Cui, J.; Kuffer, C.; Boxhammer, R.; Harrison, C. |
| Abstract Title: | Pelabresib plus ruxolitinib combination therapy in jak inhibitor-naïve patients with myelofibrosis in the phase 3 MANIFEST-2 study: Preliminary evidence of bone marrow recovery |
| Meeting Title: | 12th Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) |
| Keywords: | myelofibrosis; clinical trial; bone marrow; microenvironment; phase 3; mpn; pelabresib |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 24 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2024 Sep 4-7 |
| Meeting Location: | Houston, TX |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2024-09-01 |
| Start Page: | S417 |
| End Page: | S418 |
| Language: | English |
| ACCESSION: | WOS:001315579604038 |
| PROVIDER: | wos |
| DOI: | 10.1016/S2152-2650(24)01404-6 |
| Notes: | Meeting Abstract: MPN-136 -- Source: Wos |
